Samidorphan

Drug Profile

Samidorphan

Alternative Names: ALKS 33; RDC-0313; RDC-0313-00

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Rensselaer Polytechnic Institute
  • Developer Alkermes; Alkermes plc
  • Class Amides; Cyclopropanes; Drug withdrawal therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alcoholism; CNS disorders; Drug abuse; Eating disorders

Most Recent Events

  • 17 Dec 2015 No development reported - Phase-I for CNS disorders (In volunteers) in USA (PO)
  • 17 Dec 2015 No development reported - Phase-I for Drug abuse (In volunteers) in USA (PO)
  • 17 Dec 2015 No development reported - Phase-II for Alcoholism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top